



## **PEDANIOS 22/1 DNK**

Medical Cannabis Product distributed in the UK

| Active ingredient:<br>Dominant:<br>Cultivar: | Approx. 22% THC<br><1% CBD<br>Sativa<br>Ghost Train Haze |                    | H<br>AURORA<br>PEDANIOS 22/I<br>Medimai-Carnababilien<br>ce.22%TMC < 1%CBD  | DNK |
|--|--|--------------------|---|-----|
| Ingredients:                                 |  | Shown as a percent | - 15%<br>6% - 4% - 3%<br>age of the total terpen<br>arages over multiple ba |     |

| Terpene <sup>1</sup> | Terpinolene   | Eucalyptol          |
|----------------------|---------------|---------------------|
| Scent                | sweet, fruity | fresh, camphor-like |

1. Russo E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163: 1344-1364.

## **PEDANIOS 22/1 DNK**

## **TITRATION GUIDE**

- There is currently no uniform starting dose for cannabis products nor uniform dosing information.
- Patients are recommended to slowly titrate up to find their optimal dose for maximum therapeutic effects and minimal adverse effects.
- Timing of onset depends on mode of administration.

## Onset and duration of effects for inhalation and oral adminstration<sup>2</sup>

|                       | Inhalation |                                     | Oral administration |                                     |
|-----------------------|------------|-------------------------------------|---------------------|-------------------------------------|
| Onset of Effect       |            | Within seconds to minutes           | Ŀ                   | Within 30 minutes to<br>2 hours     |
| Peak Effects          | Ŀ          | Full effects peak within 30 minutes | Ŀ                   | Full effects peak<br>within 4 hours |
| Duration of<br>Effect | Ŀ          | Up to 6 hours or<br>longer          | Ŀ                   | Up to 12 hours or<br>longer         |

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

> Adverse events should also be reported to: IPS Pharma | medicalcannabis@ipsspecials.com | 0800 644 0747



Aurora Medicine UK Limited | 5th Floor | 14-16 Dowgate Hill | London EC4R 2SU | United Kingdom

2. Minister of Health HC, Health Canada. Health Effects of Cannabis.; 2017.

Aurora Medicine UK Limited | www.auroramedicine.com